Brain Parenchymal Fraction in Healthy Adults—A Systematic Review of the Literature

por Vågberg, Mattias, Granåsen, Gabriel, Svenningsson, Anders
Publicado en PLoS One (2017)

Serum sickness following rituximab therapy in multiple sclerosis

por Holmøy, Trygve, Fogdell-Hahn, Anna, Svenningsson, Anders
Publicado en Neurol Clin Pract (2019)

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

por Bergman, Joakim, Burman, Joachim, Bergenheim, Tommy, Svenningsson, Anders
Publicado en J Neurol (2020)

Inflammatory activity and vitamin D levels in an MS population treated with rituximab

por Linden, Johan, Granåsen, Gabriel, Salzer, Jonatan, Svenningsson, Anders, Sundström, Peter
Publicado en Mult Scler J Exp Transl Clin (2019)

Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS

por Bergman, Joakim, Svenningsson, Anders, Liv, Per, Bergenheim, Tommy, Burman, Joachim
Publicado en Fluids Barriers CNS (2020)

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden

por Wickström, Anne, Sundström, Peter, Wickström, Lucas, Dahle, Charlotte, Vrethem, Magnus, Svenningsson, Anders
Publicado en Mult Scler J Exp Transl Clin (2015)

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction

por Vågberg, Mattias, Norgren, Niklas, Dring, Ann, Lindqvist, Thomas, Birgander, Richard, Zetterberg, Henrik, Svenningsson, Anders
Publicado en PLoS One (2015)

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis

por Granqvist, Mathias, Boremalm, Malin, Poorghobad, Amyar, Svenningsson, Anders, Salzer, Jonatan, Frisell, Thomas, Piehl, Fredrik
Publicado en JAMA Neurol (2018)

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing

por Carlsson, Henrik, Rollborn, Niclas, Herman, Stephanie, Freyhult, Eva, Svenningsson, Anders, Burman, Joachim, Kultima, Kim
Publicado en Metabolites (2021)

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls

por de Flon, Pierre, Söderström, Lars, Laurell, Katarina, Dring, Ann, Sundström, Peter, Gunnarsson, Martin, Svenningsson, Anders
Publicado en PLoS One (2018)

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally

por Svenningsson, Anders, Bergman, Joakim, Dring, Ann, Vågberg, Mattias, Birgander, Richard, Lindqvist, Thomas, Gilthorpe, Jonathan, Bergenheim, Tommy
Publicado en Neurol Neuroimmunol Neuroinflamm (2015)

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS

por Bergman, Joakim, Dring, Ann, Zetterberg, Henrik, Blennow, Kaj, Norgren, Niklas, Gilthorpe, Jonathan, Bergenheim, Tommy, Svenningsson, Anders
Publicado en Neurol Neuroimmunol Neuroinflamm (2016)

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness

por Penner, Iris-Katharina, Sivertsdotter, Eva Catharina, Celius, Elisabeth G., Fuchs, Siegrid, Schreiber, Karen, Berkö, Sara, Svenningsson, Anders
Publicado en Front Neurol (2015)

Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry

por Carlsson, Henrik, Abujrais, Sandy, Herman, Stephanie, Khoonsari, Payam Emami, Åkerfeldt, Torbjörn, Svenningsson, Anders, Burman, Joachim, Kultima, Kim
Publicado en Metabolomics (2020)

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light

por Al Nimer, Faiez, Thelin, Eric, Nyström, Harriet, Dring, Ann M., Svenningsson, Anders, Piehl, Fredrik, Nelson, David W., Bellander, Bo-Michael
Publicado en PLoS One (2015)

Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study

por Söderholm, Jonas, Yilmaz, Aylin, Svenningsson, Anders, Büsch, Katharina, Wejstål, Rune, Brolund, Alma, Kövamees, Jan, Sällberg, Matti, Lagging, Martin, Gisslén, Magnus
Publicado en J Neurol (2019)

Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting

por Svenningsson, Anders, Falk, Eva, Celius, Elisabeth G., Fuchs, Siegrid, Schreiber, Karen, Berkö, Sara, Sun, Jennifer, Penner, Iris-Katharina, for the TYNERGY trial investigators
Publicado 2013

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein

por Novakova, Lenka, Zetterberg, Henrik, Sundström, Peter, Axelsson, Markus, Khademi, Mohsen, Gunnarsson, Martin, Malmeström, Clas, Svenningsson, Anders, Olsson, Tomas, Piehl, Fredrik, Blennow, Kaj, Lycke, Jan
Publicado en Neurology (2017)

Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers

por Khademi, Mohsen, Dring, Ann M., Gilthorpe, Jonathan D., Wuolikainen, Anna, Al Nimer, Faiez, Harris, Robert A., Andersson, Magnus, Brundin, Lou, Piehl, Fredrik, Olsson, Tomas, Svenningsson, Anders
Publicado 2013

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination

por Al Nimer, Faiez, Elliott, Christina, Bergman, Joakim, Khademi, Mohsen, Dring, Ann M., Aeinehband, Shahin, Bergenheim, Tommy, Romme Christensen, Jeppe, Sellebjerg, Finn, Svenningsson, Anders, Linington, Christopher, Olsson, Tomas, Piehl, Fredrik
Publicado en Neurol Neuroimmunol Neuroinflamm (2016)